The National Institute on Aging (NIA) awarded a $341,000 Project Grant (CFDA 93.866 - Aging Research) to The Roskamp Institute, Inc. in Sarasota, FL. The grant will support research to investigate the impact of the APOE4 genotype, a major genetic risk factor for Alzheimer's disease, on brain bioenergetics. The goal is to examine how APOE4-mediated disturbances in fatty acid metabolism and energy substrate availability within the cerebrovascular system and astrocytes contribute to neuronal energy...
This Project Grant award from the National Institute on Aging (CFDA 93.866, Aging Research) provides $1,489,256 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the effects of a ketogenic diet on brain energy metabolism in aging and Alzheimer's disease. The key products and services to be delivered under this award include: 1) Developing advanced magnetic resonance spectroscopy techniques to measure biomarkers of brain energy metabolism, including...
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
The federal Project Grant award R01AG092390, totaling $804,450.00, was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The grant aims to investigate the mechanisms by which the Alzheimer's disease genetic risk factor ApoE4 interacts with sex and aging to contribute to neuronal dysfunction and cognitive decline. Key objectives include validating the protective effects of the protein NELL2 in hippocampal excitatory neurons, and examining the...
This Project Grant award, funded by the National Institute on Aging's Aging Research program (CFDA 93.866), supports research to investigate how the APOE genotype affects the production and composition of mitovesicles, a type of extracellular vesicle derived from mitochondria, in the brain. The $2,499,343 award, with a performance period from Sep 1, 2024 to Aug 31, 2027, will be led by the Research Foundation for Mental Hygiene, Inc. (RFMH) at the Nathan S. Kline Institute. The project aims to...
The National Institute on Aging (NIA) awarded a $405,849 Project Grant (CFDA 93.866 - Aging Research) to the Keck Graduate Institute of Applied Life Sciences to investigate the impact of obesity-induced hepatic amyloid beta dysregulation on Alzheimer's disease pathology. The key objectives are to: Examine the relationship between changes in peripheral and hepatic amyloid beta with brain amyloid beta load and Alzheimer's disease pathology in Alzheimer's disease mice fed a high-fat/high-sugar...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Roskamp Institute, Inc. in Sarasota, Florida provides $449,460 in funding to support research investigating the role of cerebrovascular dysfunction and bioenergetic deficits in the increased Alzheimer's disease risk associated with the APOE4 genetic variant. The research aims to determine how APOE4 disrupts L-carnitine-mediated bioenergetic pathways in brain endothelial and mural cells, and...
This Project Grant award of $751,442 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to optimize and preclinically evaluate a brain-permeable CRISPR-based therapy to edit the APOE4 gene and convert it to the benign APOE3 variant in Alzheimer's disease (AD) models. The key products and services to be delivered include: Optimizing the CRISPR delivery platform using microfluidic synthetic exosomes (SE) to enhance plasma half-life and blood-brain barrier...
This $745,765 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the Icahn School of Medicine at Mount Sinai (ISMMS) in New York aims to investigate the effects of Alzheimer's disease (AD) risk genes and aging on human microglia activity and lipid metabolism. The key focus is on understanding how genetic variants associated with increased AD risk or longevity may impact microglia's ability to clear cholesterol/lipid-rich cellular debris, a critical...
The National Institute on Aging (NIA) awarded a $473,216 Project Grant (CFDA 93.866, Aging Research) to MCM6 Therapeutics, Inc. in Lexington, MA, with a project period from September 25, 2024 to August 31, 2025. The grant supports the development of a high-content screening pipeline to identify small molecule therapeutics that can reduce aberrant lipid accumulation in oligodendrocytes expressing the APOE4 gene, which is a major genetic risk factor for Alzheimer's disease. The project aims to...
The National Institute on Aging (NIA) awarded a $3,477,475 Project Grant (CFDA 93.866 - Aging Research) to the Icahn School of Medicine at Mount Sinai to investigate the combined role of the APOE4 gene and ketogenic diets in Alzheimer's disease (AD). The 5-year grant, awarded on August 15, 2024, will employ in vitro models of human brain tissue and APOE-humanized mice to discover the underlying mechanisms by which APOE4 interacts with high-fat/ketogenic diets to exacerbate AD pathogenesis. The research aims to identify therapeutic targets for promoting beneficial APOE4-diet interactions and provide a detailed molecular understanding of the links between genetics, diet, and neurodegeneration to inform genetically-tailored treatments and diagnostics for Alzheimer's disease.